Adlai Nortye

Update in progress

ANL (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Adlai Nortye Ltd. is a clinical-stage company that develops pharmaceutical products through its subsidiaries. Its pipeline includes AN0025, a small-molecule EP4 antagonist in phase Ib for rectal and esophageal cancer, with phase II in high-risk rectal cancer; AN9025, a pan-RAS(ON) inhibitor in phase 1a; AN4035, a CEACAM5-targeting ADC; AN8025, a trispecific antibody fusion in phase Ia; and AN4005, a PD-L1 inhibitor in phase 1b. It also offers tech transfer and consulting. Founded 2004, North Brunswick, NJ.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive